Wenbin Liu

Fuma Road 420#
Fuzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Toxicity spectrum of taxanes: a safety analysis from pre-marketing to post-marketing.

Toxicity spectrum of taxanes: a safety analysis from pre-marketing to post-marketing.

Journal: Expert opinion on drug safety
Published: February 17, 2025

Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.

Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model.

Journal: BMJ open
Published: January 20, 2025

Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking.

Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking.

Journal: Technology and health care : official journal of the European Society for Engineering and Medicine
Published: March 22, 2024

Application of a WeChat Mini Program to provide pharmaceutical care for cancer pain patients: A randomized controlled trial.

Application of a WeChat Mini Program to provide pharmaceutical care for cancer pain patients: A randomized controlled trial.

Journal: Digital health
Published: December 12, 2023

Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma.

Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma.

Journal: Biochemical genetics
Published: October 25, 2023

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.

Journal: Cost effectiveness and resource allocation : C/E
Published: January 29, 2023

Research of Active Compounds from Allii Macrostemonis Bulbus and Potential Targets against Non-Hodgkin's Lymphoma Based on Network Pharmacology.

Research of Active Compounds from Allii Macrostemonis Bulbus and Potential Targets against Non-Hodgkin's Lymphoma Based on Network Pharmacology.

Journal: Current computer-aided drug design
Published: December 22, 2022

An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.

An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.

Journal: Clinical and experimental medicine
Published: November 15, 2022

YouTube as a platform to better understand the treatment of lymphoma using ibrutinib: a cross-sectional study.

YouTube as a platform to better understand the treatment of lymphoma using ibrutinib: a cross-sectional study.

Journal: Annals of translational medicine
Published: June 20, 2022
Showing 1-9 of 9

Last Updated: 09/26/2026